Undisclosed US biotech licenses Vernalis' adenosine antagonist program; partner is Corvus
An undisclosed private US biotech licensed exclusive global rights to Vernalis PLC's adenosine receptor antagonist program, including lead candidate V81444 (BIIB034), in Phase I/II for Parkinson's disease and ADHD.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.